Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Carcinoma, Small Cell 1Burkitt Lymphoma 1

Interventions

Dexamethasone 4nelarabine 3Calcium Dobesilate 2terameprocol 1ontuxizumab 1mogamulizumab 1isatuximab 1forodesine 1fludarabine phosphate 1fludarabine 1crenigacestat 1cobomarsen 1calaspargase pegol 1brincidofovir 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Sensitivity and Specificity 1Ranitidine 1Oxaliplatin 1Mycophenolic Acid 1Mesna 1Lenalidomide 1HBI-8000 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Fentanyl 1Diphenhydramine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × BI 2536 × Clear all
NCT00243087 2024-12-20

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Boehringer Ingelheim

Phase 1 Completed
41 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡